No interaction of memantine with acetylcholinesterase inhibitors approved
for clinical use.
Wenk GL, Quack G, Moebius HJ, Danysz W.
Division of Neural Systems,
Memory & Aging, University of Arizona,
Tucson, AZ, 85724, USA gary@nsma.arizona.edu
Life Sci 2000 Feb 11;66(12):1079-83
Abstract
The loss of cholinergic neurons within the basal forebrain of patients with Alzheimer's disease (AD) may underlie aspects of the dementia. Excessive activation of N-methyl-D-aspartate (NMDA) receptors may underlie the degeneration of cholinergic cells.
New drug therapies have been designed to either enhance cholinergic function by inhibition acetylcholinesterase (AChE), e.g. galanthamine, tetrahydroaminoacridine or donepezil, or by attenuation of NMDA receptor function, e.g.
memantine. A combination of these two therapeutic approaches may be more beneficial at slowing the progression of the AD. The current study investigated whether
memantine would attenuate the inhibition of AChE produced by these three drugs. The results indicate that these AChE inhibitors do not lose their therapeutic efficacy in combination with
memantine. Our in vitro data suggest that the clinical combination of
memantine with a reversible AChE inhibitor should be a valuable
pharmacotherapeutic approach to dementia.
